摘要
目的:探究高通血液透析联合碳酸司维拉姆对维持性血液透析老年患者继发高磷血症的疗效。方法:选取皖南医学院附属太和医院2016年12月-2021年1月纳入的80例维持性血液透析老年患者,按照随机数字表法分为对照组(n=40)和观察组(n=40)。两组均予以常规血液透析,在此基础上,对照组采用碳酸司维拉姆治疗,观察组采用高通血液透析联合碳酸司维拉姆治疗。评估两组临床疗效、血钙、血清磷、甲状旁腺激素(PTH)、白细胞介素-6(IL-6)、C反应蛋白(CRP)水平及不良反应发生情况。结果:观察组治疗总有效率为97.50%,高于对照组的85.00%(P<0.05);治疗后,观察组血钙水平高于对照组,血清磷、PTH水平均显著低于对照组(P<0.05);治疗后,观察组IL-6及CRP水平均显著低于对照组(P<0.05);观察组与对照组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:高通血液透析联合碳酸司维拉姆对维持性血液透析老年患者继发高磷血症具有良好的临床疗效,能有效调节钙磷代谢指标,降低血清炎症因子水平及不良反应的发生率。
Objective:To explore the effect of qualcomm hemodialysis combined with Sevelamer Carbonate on secondary hyperphosphatemia in elderly patients undergoing maintenance hemodialysis.Method:A total of 80 elderly patients with maintenance hemodialysis enrolled in Wannan Medical College Affiliated Taihe Hospital from December 2016 to January 2021 were divided into control group (n=40) and observation group (n=40) according to random number table method.Routine hemodialysis was performed in both groups.On this basis,the control group was treated with Sevelamer Carbonate,the observation group was treated with qualcomm hemodialysis combined with Sevelamer Carbonate.The clinical efficacy,serum calcium,serum phosphorus,parathyroid hormone (PTH),interleukin-6 (IL-6),C reactive protein (CRP) levels and the incidence of adverse reactions were evaluated in both groups.Result:The total effective rate in observation group was 97.50%,which was higher than 85.00% in control group (P<0.05);after treatment,the level of serum calcium in observation group was higher than that in control group,while the levels of serum phosphorus and PTH were significantly lower than those in control group (P<0.05);after treatment,the levels of IL-6 and CRP in observation group were significantly lower than those in control group (P<0.05);there was no significant difference in the incidence of adverse reactions between observation group and control group (P>0.05).Conclusion:Qualcomm hemodialysis combined with Sevelamer Carbonate has a good clinical effect on secondary hyperphosphatemia in elderly patients with maintenance hemodialysis,which can effectively regulate calcium and phosphorus metabolism indicators,reduce the level of serum inflammatory factors,and reduce the incidence of adverse reactions.
作者
伲雷
NI Lei(Wannan Medical College Affiliated Taihe Hospital,Taihe 236600,China)
出处
《中国医学创新》
CAS
2022年第11期58-61,共4页
Medical Innovation of China
关键词
高通血液透析
碳酸司维拉姆
维持性血液透析
高磷血症
Qualcomm hemodialysis
Sevelamer Carbonate
Maintenance hemodialysis
Hyperphosphatemia
